ArticleCardiovascular diabetology2019

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.

Lindsay E Clegg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.